Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4‐quinolone broad‐spectrum antibiotic

Cutaneous photosensitivity reactions are a consistent although uncommon feature of the fluoroqui‐nolone group of antihiotics, which are related to nalidixic acid. Ohjective laboratory and clinical data are now routinely required by regulatory bodies for new drugs suspected of being photosensitizers. but no clear recommendations exist. A series of in vitro tests ranging in complexity revealed a UVA‐dependent phototoxic potential for the fluoroquinolone norfloxacin similar to that for ciprofloxacin. and less than that of nalidixic acid. Controlled monochromator phototesting, designed to reveal the clinical characteristics, wavelength dependence and severity of cutaneous reactions in normal subjects showed both norfloxacin and ciproHoxacin to have a weak phototoxic potential which clears within 4 weeks of stopping the drug. UVA wavelengths (335±30 nm: 365±30 nm) appear most responsible for producing an asymptomatic erythema which is maximal at 24 h.

[1]  D. Hooper,et al.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans , 1985, Antimicrobial Agents and Chemotherapy.

[2]  W. Frain-Bell,et al.  A study of benoxaprofen‐induced photosensitivity , 1982, The British journal of dermatology.

[3]  W. Bowie,et al.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin , 1989, Antimicrobial Agents and Chemotherapy.

[4]  W. Frain-Bell,et al.  The construction and development of a grating monochromator and its application to the study of the reaction of the skin to light , 1973, The British journal of dermatology.

[5]  G. Stein.  Review of the bioavailability and pharmacokinetics of oral norfloxacin. , 1987, The American journal of medicine.

[6]  J. Ring,et al.  Demonstration of quinolone phototoxicity in vitro. , 1990, Dermatologica.

[7]  J. Laragh.  Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment. , 1989, The American journal of medicine.

[8]  E V Granowitz,et al.  Photosensitivity rash in a patient being treated with ciprofloxacin. , 1989, The Journal of infectious diseases.

[9]  N. Mizuno,et al.  Photoallergic reaction caused by enoxacin. , 1989, Photo-dermatology.

[10]  H. Halkin.  Adverse effects of the fluoroquinolones. , 1988, Reviews of infectious diseases.

[11]  P. Ball,et al.  Ciprofloxacin: an overview of adverse experiences. , 1986, The Journal of antimicrobial chemotherapy.

[12]  D. Robertson,et al.  Mechanistic studies of the phototoxic potential of PD 117596, a quinolone antibacterial compound. , 1991, Toxicology and applied pharmacology.

[13]  E. Walker,et al.  In Vitro Models for Cutaneous Phototoxicity , 1986 .

[14]  N. Høiby,et al.  The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. , 1987, The Journal of antimicrobial chemotherapy.

[15]  W. Frain-Bell,et al.  A study of cutaneous photosensitivity induced by amiodarone , 1985, The British journal of dermatology.

[16]  S T Nedorost,et al.  Drug-induced photosensitivity reaction. , 1989, Archives of dermatology.

[17]  R. C. Johnson,et al.  Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. , 1989, Reviews of infectious diseases.

[18]  J Ferguson,et al.  Ciprofloxacin‐induced photosensitivity: in vitro and in vivo studies , 1990, The British journal of dermatology.

[19]  H. Neu.  Chemical evolution of the fluoroquinolone antimicrobial agents. , 1989, The American journal of medicine.

[20]  B. O’Brien,et al.  Ciprofloxacin: an update on clinical experience. , 1987, The American journal of medicine.

[21]  A. Zelickson.  PHOTOTOXIC REACTION WITH NALIDIXIC ACID. , 1964, JAMA.